FOXO4-DRI vs Teriparatide
A side-by-side research comparison of FOXO4-DRI and Teriparatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FOXO4-DRI | Teriparatide |
|---|---|---|
| Full name | FOXO4-D-Retro-Inverso Peptide (Senolytic) | Teriparatide (PTH 1-34) |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | FDA-approved drug (prescription) |
| Mechanism | Competitively disrupts FOXO4 sequestration of p53 in senescent cells, releasing p53 to trigger intrinsic apoptosis selectively in cells relying on this survival mechanism. | Intermittent dosing of PTH 1-34 preferentially stimulates osteoblasts (bone-building cells) over osteoclasts, increasing bone formation, trabecular bone mass, and bone strength. |
| Molecular weight | ~4,500 Da | 4117.8 Da |
| Half-life | 12-24 hours (D-amino acid stability) | ~1 hour (subcutaneous) |
| Bioavailability | Moderate (SubQ) | ~95% subcutaneous |
| Typical dose | 5-10 mg/kg (animal studies) | 20 mcg once daily (medical) |
| Frequency | 3x per week for 3 weeks | Once daily |
| Route | Subcutaneous | Subcutaneous injection |
FOXO4-DRI reported benefits
- Selective senescent cell elimination
- Potential aging reversal
- Improved tissue function
- Reduced inflammatory burden
- Hair regrowth (mice)
Teriparatide reported benefits
- Actively builds new bone
- Increases bone mineral density
- Reduces fracture risk (medical)
- Supports bone healing
Related comparisons
Research and educational reference only. Not medical advice.